The collaboration, funded by GSK, will apply Jvion’s artificial intelligence solution to detect COPD inpatients at Geisinger who are at risk of a readmission within 30 days of discharge. The AI solution, called the “cognitive clinical success machine,” uses data analytics to identify actions and medications — such as clinical trials — that may reduce patients’ likelihood of readmission.
A second phase of the collaboration will involve identifying patients with COPD who are at risk for an avoidable hospitalization.
“GSK is committed to improving COPD disease management and we believe that the use of cognitive machine technology will improve our ability to assess the potential of novel therapies for individuals at risk of COPD hospital admission by selecting the right patients for clinical trials,” said Ruth Tal-Singer, vice president of medicine development leader at GSK.
More articles on data analytics & precision medicine:
Harvard, IBM researchers develop prediction model for cirrhosis outcomes
Johns Hopkins, Northwestern among institutions leading new National Center for Data to Health
78% of physician leaders cite ‘incomplete data’ as a top threat to patient safety, survey finds
